According to the Company, the generic product will launch immediately. The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ®. Liraglutide is ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), significantly improving access to diabetes treatment. The glucagon-like peptide-1 ...

It will be available tomorrow, day 1 of patent expiry, the Hyderabad-based generic drugmaker said on Friday. Semaglutide is ...

The vial format provides doctors flexibility in dosing, he explained, adding that micro-dosing by patients would require ...

Looking to enter India’s ₹1,446 crore glucagon-like peptide (GLP-1) market, Hyderabad-based pharma major Dr Reddy’s Laboratories (DRL) has launched its semaglutide generic, Obeda, for Type 2 diabetes ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. For the first time, a generic GLP-1 has been approved by ...

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), Monday announced the launch of an authorized generic for Victoza injection with a quantity of 1.8 mg for type 2 diabetes patients in the U.S.

Coverage of key CVD medications in low-cost generic drug programs in the United States differs by plan, medication type, and condition, according to an analysis published recently online in Annals of ...

The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who are 10 years old and up with Type 2 diabetes. The liraglutide injection, ...